Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
UK biotech Circassia Pharmaceuticals today announced the appointment of Jonathan Emms to the newly-created role of chief operating officer (COO). 12 August 2019
US pharma major Eli Lilly announced several leadership changes in the company's corporate business development, oncology R&D, and managed healthcare services organizations before markets opened this morning. 7 August 2019
Immunotherapeutics developer Imcyse today announced the appointment of seasoned biotech expert Thomas Taapken as executive chairman and chairman of the board. 5 August 2019
A month after announcing that Adrian Rawcliffe is to succeed the retiring James Noble as chief executive in September, Adaptimmune has revealed further management changes. 2 August 2019
US drugmaker Vertex Pharmaceuticals today revealed that its board has approved a planned transition of chairman, president and chief executive Dr Jeffrey Leiden, into the role of executive chairman of the board, effective April 1, 2020. 25 July 2019
Emirati company Julphar, one of the largest pharmaceutical manufacturers in the Middle East and North Africa (MENA), has announced the appointment of new executives to help guide the company towards profitability and long-term success. 22 July 2019
Julian Gilbert, the founder of Anglo-American company Acacia Pharma Group, is to step down from his role as chief executive and director at the end of the month. 18 July 2019
Gilead Sciences announced today that John McHutchison, chief scientific officer and head of R&D, has decided to leave the company, effective next month. 17 July 2019
US biotech major Gilead Sciences has lured high pharma profile Christi Shaw to the company as chief executive of CAR-T cancer therapy specialist Kite. 12 July 2019
US RNAi therapies specialist Alnylam yesterday announced that Jeff Poulton joined the company on July 11, 2019, and has been appointed executive vice president and chief financial officer (CFO), effective August 13. 12 July 2019
Privately-held German biotech firm Immatics Biotechnologies today announced that Harpreet Singh has been appointed the company’s chief executive (CEO). 8 July 2019
After the failure of its latest drug candidate in clinical trials, US oncology specialist Merrimack Pharmaceuticals has issued a document to the US Securities and Exchange Commission, announcing the departure of the company’s top two executives. 4 July 2019
French nanomedicine company Nanobiotix today announced organizational changes to align with strategic priorities post European market approval for Hensify (NBTXR3), which was cleared for marketing in April. 1 July 2019
Ever since Dr Scott Gottlieb unexpectedly stepped down as head of the US Food and Drug Administration in March this year, less than two years into his tenure, there has been speculation about where he would re-appear 28 June 2019
USA-based antibacterial products developer Entasis Therapeutics has announced the appointment of David Meek, currently chief executive of French pharma company Ipsen, as chairman of the board of directors, effective immediately. 25 June 2019
German drugmaker Stada Arzneimittel has nominated a successor for Enrique Häusermann, the long-time general manager of its Italian unit EG SpA. 20 June 2019
Valo Therapeutics, a cancer immunotherapy company developing neoantigen-coated oncolytic viruses as therapeutic vaccines, has appointed Dr Michael Stein to the full-time role of chief executive, having served as part-time co-chairman since inception in January 2017. 17 June 2019